b r i e f c o m m u n i c at i o n s Neutralizing antibodies (NAbs) increase in titer and avidity during HIV-1 infection 1 and, in many people, mature to neutralize divergent isolates, targeting diverse epitopes of the envelope protein (Env). A fraction of NAbs target conserved regions on Env, including the CD4 binding site (CD4bs) 2, 3 , as in the case of the human neutralizing monoclonal antibody (NmAbs) IgG1b12 (ref. 4 ). HIV-1positive pregnant mothers transfer HIV-1-specific IgG across the placenta to the fetus in utero, and mother-to-child transmission of the virus frequently occurs in the presence of NAbs, which can mediate selection of transmitted variants 5 . Passive administration of high amounts of polyclonal neutralizing IgG or NmAbs can fully protect against high-dose intravenous 6 or mucosal 7, 8 SHIV challenge in nonhuman primates. Lower amounts of NmAbs can prevent infection from high-dose 9 or serial low-dose mucosal SHIV challenge in macaques when infused repeatedly 10 . Non-neutralizing antibodies, such as antibody-dependent cell-mediated viral inhibition (ADCVI)-mediating antibodies, are also found during HIV-1 and SIV infection and may reduce viral load via natural killer or monocyte effector cells that kill infected cells 11 . Passive infusion of non-neutralizing serum with potent ADCVI activity prevents infection in newborn rhesus macaques 12 . A key remaining question is whether maternal antibodies in HIV-positive mothers might have a role in limiting viremia in newborns that are infected.
Previously, we showed that early treatment (a two-dose regimen on days 1 and 14) of six SIV-infected juvenile macaques with highdose SIV-specific neutralizing IgG (SIVIG) accelerated NAb development by 20 weeks 13 , accompanied by tight control of viremia for 5 years in the three macaques that seroconverted. Another group also showed substantial control of SIV plasma viremia by passive transfer of SIVIG on day 7 (ref. 14) . In this study, we used a SHIV challenge model in newborn macaques to ask whether NAbs at physiological, nonprotective doses could limit viremia and CD4 + T cell destruction in these animals. We subcutaneously inoculated groups of six macaques with IgG from uninfected macaques (normal IgG), matched IgG (specific to SHIVIG SF162P3 ) plus IgG1b12 or mismatched IgG (specific to SHIVIG 89.6P ) 1 d before high-dose (two half-maximal animal infectious doses) oral inoculation with SHIV SF162P3 (Supplementary Methods). We previously showed that SHIV SF162P3 is vertically transmitted and highly pathogenic in newborn macaques 15 . To ensure that the SHIVIG included a CD4bs-directed NAb, we incorporated IgG1b12, a potent, broadly reactive human NmAb directed to the CD4bs that neutralizes SHIV SF162P3 (ref. 4) , in a ratio of 1 in 1,000 (wt/wt; ~2.5 μg ml −1 in vivo). The characteristics of the IgG preparations are summarized in Supplementary Table 1 . At the doses delivered in vivo, matched IgG neutralized 93% of the challenge virus in vitro, whereas mismatched IgG neutralized 60% ( Fig. 1a) . Up to 24 weeks after infection, although several macaques developed gp120-specific antibodies, only one macaque in the normal IgG group and two in the mismatched IgG group developed de novo NAbs, as indicated by increasing levels above the passive transfer levels ( Supplementary  Fig. 3a,b,d,e ).
Exposure to SHIV SF162P3 resulted in the infection of five of six macaques given normal IgG, all six macaques given matched IgG and five of six macaques given mismatched IgG, as determined by DNA realtime PCR ( Supplementary Table 1 and Supplementary Fig. 1 ). Peak peripheral blood mononuclear cell-associated viremia was delayed by 1 week in both the matched and mismatched groups ( Fig. 1c) . At 1 week after infection, proviral load was significantly lower in the matched IgG (P = 0.0159, Mann-Whitney U test) and mismatched IgG (P = 0.0159) groups compared to the normal IgG group, but this control of virus replication was not maintained after 2 weeks. Similar to the cell-associated viremia, there was a 1-week delay in peak plasma viral load in both the matched IgG and mismatched IgG groups compared with normal IgG ( Fig. 1d and Supplementary Fig. 2 Maternal HIV-1-specific antibodies are efficiently transferred to newborns, but their role in disease control is unknown. We administered neutralizing IgG, including the human neutralizing monoclonal IgG1b12, at levels insufficient to block infection, to six newborn macaques before oral challenge with simian-HIV strain SF162P3 (SHIV SF162P3 ). All of the macaques rapidly developed neutralizing antibodies and had significantly reduced plasma viremia for six months. These studies support the use of neutralizing antibodies in enhancing B cell responses and viral control in perinatal settings.
b r i e f c o m m u n i c at i o n s as area under the curve minus baseline (AUC, Mann-Whitney U test) were significant in the matched IgG group compared to the normal IgG group (P = 0.0173) but not the mismatched IgG group versus the normal IgG group (P = 0.6905) ( Fig. 1e) . Steady-state virus levels (weeks 8-24) were significantly different between the normal IgG group and the matched IgG group (P = 0.0303) but not the mismatched IgG group (P = 0.5556) ( Fig. 1f) .
Comparatively, matched IgG neutralized only 65% of SHIV 89.6P , whereas mismatched IgG neutralized 90%. Comparing each of the two experimental groups with the normal IgG control, the total gp120-specific IgG abundance (AUC, 8-24 weeks) in the matched IgG group was significantly higher than in the normal IgG group (P = 0.0303), but the abundance in the mismatched IgG group was not (P = 1.0). By 24 weeks after infection, mean gp120-specific IgG titers in the matched IgG group were 19-fold higher than in the mismatched IgG group and tenfold higher than the normal IgG group. All groups had similar antibody kinetics and titers elicited by the concurrently administered hepatitis B vaccine (P > 0.3; Supplementary Fig. 4 ), a control for non-HIV-1-specific B cell responses.
To measure NAb titers, we used a single pseudovirus cloned from the challenge stock in the TZM-bl neutralization assay 15 . Env clones in the challenge stock were 0.5% divergent (Supplementary Fig. 5 ) and showed a range of sensitivity to neutralization ( Supplementary  Fig. 6a ). On the day of challenge, we detected no NAbs in the normal IgG group. Only one developed detectable NAbs before 24 weeks, and two of five infants given normal IgG had detectable NAbs only at 24 weeks after infection (Supplementary Fig. 3d ). On the day of challenge, two macaques in the mismatched IgG group had neutralizing activity just above the detection level, which was not unexpected, as this preparation can neutralize 60% of virus; these macaques developed NAbs by 6-8 weeks after infection, whereas the remaining macaques had detectable NAbs only at 24 weeks after infection (Supplementary Fig. 3e) . In contrast, all six macaques that received matched IgG had detectable NAbs on the day of challenge ( Supplementary Fig. 3f ) and developed de novo NAbs by 12 weeks after infection, many detectable as early as 6 weeks after infection, which increased in titer and persisted until necropsy. Macaques that had NAbs by week 24 neutralized most or all SHIV SF162P3 variants derived from the inoculum (Supplementary Fig. 6b ). Mean titers of NAbs (Fig. 2b) and total NAb titer (AUC, 8-24 weeks) of the matched IgG group were significantly higher than the normal IgG group (P = 0.0069), whereas the mismatched IgG group was not different by either measure (P = 0.0763). Substantial de novo ADCVI activity was restricted to the matched IgG group in which five of six macaques developed 50% inhibitory titers of ≥100 (P = 0.01, Fisher's exact test; Fig. 2c) . Several macaques given mismatched IgG had low ADCVI titers at the limit of detection (P = 0.4). Although ADCVI titers of >100 were found only in plasma from macaques with NAb responses, this degree of response was not present in all NAb-positive macaques (Supplementary Fig. 3g-i) .
There were no significant differences in total peripheral CD4 + T cell counts (Supplementary Fig. 7a-d) . However, by 24 weeks after infection, none of the five surviving macaques given matched IgG had CD4 + T cell counts of <250 cells per μl plasma (one macaque was killed early, but not owing to low CD4 + cell counts), whereas seven of ten macaques in the normal IgG and mismatched IgG groups experienced CD4 + T cell loss with counts decreasing to <500 cells per μl plasma by week 12 after infection. Six of the ten progressed to <250 CD4 + T cells per μl plasma (Fig. 2d) . Macaques that developed NAbs, regardless of treatment, by week 8 maintained higher CD4 + T cell counts than those that did not (P = 0.002, Mann-Whitney U test; Supplementary  Fig. 7e) . One of the ten macaques that developed NAbs regardless of treatment had a CD4 + T cell count <250 cells per μl at the end of 24 weeks, whereas those failing to develop NAbs had CD4 + T cell counts below that threshold (P = 0.019, Fisher's exact test).
In this study, matched IgG, with no ADCVI activity and neutralizing activity well below that used to provide sterilizing protection in other passive antibody studies 6 and at a physiologic level for an SHIVinfected dam in vivo 14 , initiated rapid NAb and ADCVI development in neonatal macaques concurrent with improved control of plasma viremia. High levels of ADCVI developed only in those macaques that received the matched IgG, and an Fc effector function also may have contributed to reduced plasma viremia at later time points 16 . The ability to trigger strong NAbs and ADCVI responses provides indirect evidence that the early presence of NAbs protected B cells from the virus-induced destruction observed in HIV-1 infection 17 . Furthermore, NAb development was associated with higher CD4 + T cell counts and suppressed viral levels. Mismatched IgG that could only weakly neutralize the challenge virus failed to provide significant benefit (it failed to show differences from the normal IgG controls), underscoring the importance of dosage. Although we did not observe increased cytotoxic T lymphocyte activity in SIV-infected passively treated juvenile macaques in a previous study 13 , others have observed preservation of central memory CD4 + T cells following passive treatment during SIV infection 14 . It is likely that the improved B cell responses in this study were accompanied by enhanced T cell responses, which we did not measure in this study owing to blood sample size limitation.
Although we do not know the extent to which IgG1b12 within the matched IgG contributed to the early control of viremia and enhanced antibody production, the addition of IgG1b12 only increased the neutralization activity in the matched IgG group by 10%, and was less than 0.2 mg per kg body weight, half an order of magnitude lower than the amount shown to be protective against repeated low-dose vaginal challenge with the same SHIV 10 . This finding is noteworthy because it suggests that small amounts of NmAbs directed to the CD4bs or other key regions could be used to augment native immunity. The potential benefit is greatest for the prevention of mother-to-child transmission, where potent, broadly neutralizing NmAbs such as the recently discovered PG9/PG16 (ref. 18 ) and VRC01 (ref. 19 ) could be delivered to mothers before delivery or to newborns at parturition and during the period of breastfeeding. Future studies will be directed toward using this nonhuman primate model to explore the protective and immunomodulatory effects of combination NmAb therapy and to understand the mechanisms underlying its beneficial effects.
All macaque studies were approved by the Institutional Animal Care and Use Committee at the University of Washington.
